| Original language | English (US) |
|---|---|
| Pages (from-to) | 807-808 |
| Number of pages | 2 |
| Journal | Clinical Infectious Diseases |
| Volume | 49 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2009 |
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Clinical Infectious Diseases, Vol. 49, No. 5, 01.09.2009, p. 807-808.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply to Bruss
AU - Cosgrove, Sara E.
AU - Fowler, Vance G.
AU - Corey, G. Ralph
AU - Karchmer, Adolf W.
AU - Boucher, Helen W.
N1 - Funding Information: Potential conflicts of interest. The study [2] referred to in the letter was funded by Cubist Pharmaceuticals. S.E.C. has received grant funding from Astellas Pharma, Cubist, and AdvanDx; has served as a consultant to Merck; and has served on advisory boards for Astellas/Theravance, Forest Pharmaceuticals, and Ortho-McNeil. V.G.F. has served as a consultant to Astellas, Biosynexus, Cubist, Inhibitex, Johnson & Johnson, Leo Pharmaceuticals, Merck, and Theravance; has received honoraria from Astellas, Cubist, Johnson & Johnson, Merck, Nabi, Pfizer, and Theravance; and has received grants from Cerexa, Cubist, Inhibitex, Merck, Nabi, and Theravance. G.R.C. has served as a consultant to AstraZeneca, Astellas, Cempra, Cerexa, Cubist, Innocoll, Merck, Pfizer, Shire, Sky-line Ventures, and Theravance; and has served on advisory boards of GlaxoSmithKline, Inhibitex, Johnson & Johnson, Merck, Ortho-McNeil, Pfizer, Forest and Vicuron. A.W.K. has served as a consultant to Cubist, has received honoraria from Cubist, and has received grants from Cubist. H.W.B. has served as an advisor/consultant to Bas-ilea, Cubist, Johnson & Johnson, Merck, Novartis, Pfizer, Rib-X, Targanta/The Medicines Company, and Astellas/Theravance; has served as a speaker for Cubist and Novartis, and owns or has owned shares of Cubist and Pfizer. H.W.B. has not served on any speakers’ bureaus since December 2007 and has sold all shares of Cubist and Pfizer.
PY - 2009/9/1
Y1 - 2009/9/1
UR - http://www.scopus.com/inward/record.url?scp=70249130931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70249130931&partnerID=8YFLogxK
U2 - 10.1086/605288
DO - 10.1086/605288
M3 - Letter
AN - SCOPUS:70249130931
SN - 1058-4838
VL - 49
SP - 807
EP - 808
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 5
ER -